HGH Fragment 176-191 vs Tesamorelin

HGH Fragment 176-191: The unmodified C-terminal fragment of growth hormone — the original lipolytic peptide. Typical dose 250-500 mcg. Tesamorelin: FDA-approved GHRH analog for HIV-associated lipodystrophy with potent GH-releasing activity. Typical dose 1000-2000 mcg. Both fall under the Weight Management and Growth Hormone categories.

Stacking HGH Fragment 176-191 with Tesamorelin is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

HGH Fragment 176-191 is typically dosed: Once daily, morning, on an empty stomach (SubQ) for Fat loss / body recomposition; Twice daily (morning + pre-cardio), fasted for Split-dose protocol for stubborn fat. Tesamorelin is typically dosed: Once daily (SubQ) for HIV lipodystrophy (FDA approved); Once daily for Body composition / anti-aging (off-label).

HGH Fragment 176-191: Not FDA approved. Distinct from AOD-9604, which holds GRAS status as a food additive. Tesamorelin: FDA approved. Egrifta (tesamorelin) approved November 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Egrifta SV (reformulated single-vial) approved 2019.